Last reviewed · How we verify
Arcoxia®120 mg
At a glance
| Generic name | Arcoxia®120 mg |
|---|---|
| Also known as | Etoricoxib |
| Sponsor | Claudia Spies |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers (PHASE1)
- Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets (NA)
- Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery (PHASE4)
- COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined (PHASE4)
- Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arcoxia®120 mg CI brief — competitive landscape report
- Arcoxia®120 mg updates RSS · CI watch RSS
- Claudia Spies portfolio CI